|
|
|
A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: the Combination of Idela
|
|
|
|
|
|
|
|
|
|
|
|
|
Yiming Zhong, Ta-Ming Liu, and Amy J Johnson
|
|
|
|
The Ohio State University
|
Division of Hematology, Department of Internal Medicine, OSU, Columbus, OH 43210, USA
|
|
yiming.zhong@osumc.edu
|
|
|
|
|
|
|
|
|
|
|
In a multi-center, randomized, double-blind, placebo-controlled phase III study reported in the New England Journal of Medicine 1, the combination of idelalisib and rituximab shows outstanding clinical activity as well as adequate safety in the treatment of relapsed chronic lymphocytic leukemia (CLL) patients.
|
|
|
|
|
|
|
|
|
|